CANC is up +48.0% year-to-date, compared with +15.7% for the S&P 500 index. Based on Bloomberg's defined universe of 47 healthcare and biotechnology ETFs, that return places CANC among the top 3 ...

Invesco Ltd. remains a Buy with a new price target after strong Q3 '25 results. IVZ delivered record organic growth, robust ETF inflows, and improved efficiency but faces declining fee realization ...

Shares of asset manager Invesco (IVZ) have been volatile during the second half of 2025, rising and falling on news about one of its largest and most well-known funds, the Invesco QQQ Trust (QQQ). An ...